|
- One shot to stop HIV: MITs bold vaccine breakthrough
Massachusetts Institute of Technology "One shot to stop HIV: MIT's bold vaccine breakthrough " ScienceDaily ScienceDaily, 20 June 2025 <www sciencedaily com releases 2025 06
- Supercharged vaccine could offer strong protection with just . . .
Researchers generated a strong immune response to HIV with just one vaccine dose, by adding two powerful adjuvants to the vaccine This strategy could lead to vaccines that only need to be given once, for infectious diseases including HIV or SARS-CoV-2
- Always ‘one atom away’: The long, rocky journey to an HIV . . .
Note: Lenacapavir PrEP was Science’s 2024 Breakthrough of the Year For his contribution to its development, Sundquist was awarded the AAAS Mani L Bhaumik Breakthrough of the Year Award on 8 May, along with Moupali Das,vice president, clinical development, HIV prevention and pediatrics at Gilead; and Yvette Raphael, co-founder and executive director of Advocacy for Prevention of HIV and AIDS
- Step by Step Scientists Move Closer to an HIV Vaccine . . .
In a breakthrough study published in Science, scientists from IAVI and Scripps Research have reported results from two separate but complementary Phase 1 clinical trials that demonstrate an innovative vaccination strategy might finally be able to teach the immune system how to generate bnAbs
- One Shot To Stop HIV: MITs Bold Vaccine Breakthrough
ScienceDaily reports: Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response with just one dose By combining two immune-boosting adjuvants alum and SMNP the vaccine lingers in lymph nodes for nearly a month, encouraging the body to produce a vast array of antibodies
- Groundbreaking single-dose vaccine found effective in . . .
Scientists have developed a vaccine which provides a strong immune response against HIV in mice, an advance that could lead to potent single-dose vaccines for a range of infectious diseases The
- Single-Dose HIV Vaccine Shows Promise With Dual Adjuvants . . .
“This approach is compatible with many protein-based vaccines, so it offers the opportunity to engineer new formulations for these types of vaccines across a wide range of different diseases, such as influenza, SARS-CoV-2, or other pandemic outbreaks,” says J Christopher Love, the Raymond A and Helen E St Laurent Professor of Chemical Engineering at MIT, and a member of the Koch
|
|
|